Long-Term Data from ESC 2024 Reinforces Safety, Efficacy Profile of Mavacamten in oHCM
New long-term data are highlighting the sustained benefits of mavacamten (Camzyos) among patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM).
Presented during the European Society of Cardiology (ESC) Congress 2024 and simultaneously published in the European Heart Journal, the latest data release from the MAVA-LTE trial offers evidence of the effects on left ventricular outflow tract (LVOT) gradients, NT-proBNP, and quality of life through up to 180 weeks of follow-up.
To view the third party content, kindly click on the link below or read more. You will then leave this site and enter a third party site.
Source: MDMag
